TABLE IV.

Impact of subcutaneous (SC) rituximab on systemic therapy suite time and administration cost

Variable	Study year
	1	2	3	Overall
Systemic therapy suite time (hours)
Current scenario: rituximab IV only	104,925	130,028	132,291	367,244
SC implementation scenario	72,861	84,033	81,634	238,529
Incremental savings (CA$, 2017)
Total	32,063	45,955	50,656	128,715
Patients with FL	16,278	27,595	30,832	74,705
Patients with DLBCL	15,785	18,400	19,824	54,009
Administration cost (CA$, 2017)
Current scenario: rituximab IV only	23,448,090	29,058,145	29,563,785	82,070,019
SC implementation scenario	17,065,918	19,902,854	19,480,616	56,449,388
Incremental savingsa (CA$, 2017)
Total	6,382,172	9,155,290	10,083,169	25,620,632
Patients with FL	3,240,070	5,492,846	6,137,158	14,870,074
Patients with DLBCL	3,142,103	3,662,444	3,946,011	10,750,558
Total drug and administration cost (CA$, 2017)
Current scenario: rituximab IV only	95,000,136	114,028,505	115,892,336	324,920,977
SC implementation scenario	84,869,229	99,756,912	100,201,482	284,827,623
Incremental savingsa (CA$, 2017)
Total	10,130,907	14,271,593	15,690,854	40,093,353
Patients with FL	4,942,095	8,223,499	9,174,483	22,340,077
Patients with DLBCL	5,188,811	6,048,094	6,516,371	17,753,276

^aCalculated as the difference between the current scenario and the SC implementation scenario.

IV = intravenous; FL = follicular lymphoma; DLBCL = diffuse large B-cell lymphoma.